NTI Stock Overview
A clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Neurotech International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.054 |
| 52 Week High | AU$0.13 |
| 52 Week Low | AU$0.048 |
| Beta | 1.48 |
| 1 Month Change | -19.40% |
| 3 Month Change | -10.00% |
| 1 Year Change | -10.00% |
| 3 Year Change | -6.90% |
| 5 Year Change | 237.50% |
| Change since IPO | -81.05% |
Recent News & Updates
Recent updates
Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching
Nov 19
Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans
Sep 19Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation
Jan 28We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully
Oct 14Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation
Jul 01Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?
Jan 21Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?
Oct 06Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation
May 18We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate
Dec 21Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans
Sep 04Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares
Dec 08
Shareholder Returns
| NTI | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -3.6% | -1.1% | -2.7% |
| 1Y | -10.0% | 0.4% | 6.5% |
Return vs Industry: NTI underperformed the Australian Medical Equipment industry which returned 0.4% over the past year.
Return vs Market: NTI underperformed the Australian Market which returned 6.5% over the past year.
Price Volatility
| NTI volatility | |
|---|---|
| NTI Average Weekly Movement | 9.0% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: NTI has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: NTI's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Peter James Griffiths | www.neurotechinternational.com |
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technological devices.
Neurotech International Limited Fundamentals Summary
| NTI fundamental statistics | |
|---|---|
| Market cap | AU$55.87m |
| Earnings (TTM) | -AU$5.07m |
| Revenue (TTM) | AU$3.18m |
17.6x
P/S Ratio-11.0x
P/E RatioIs NTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTI income statement (TTM) | |
|---|---|
| Revenue | AU$3.18m |
| Cost of Revenue | AU$7.83k |
| Gross Profit | AU$3.17m |
| Other Expenses | AU$8.24m |
| Earnings | -AU$5.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0049 |
| Gross Margin | 99.75% |
| Net Profit Margin | -159.54% |
| Debt/Equity Ratio | 0% |
How did NTI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 21:45 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neurotech International Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Goodsall | MST Financial Services Pty Limited |